Orchestra BioMed Holdings

Orchestra BioMed Holdings

OBIO· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +3.8% in FY2025

David P. Hochman is the CEO of Orchestra BioMed Holdings and was paid $2.3M in FY2025 (Dec), up 18%.

Pay$100 in the stock at the end of FY21 → $41
CEO pay is from each Orchestra BioMed Holdings proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1David P. HochmanFY2025
  2. 2Darren R. ShermanFY2025
  3. 3Andrew L. TaylorFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Orchestra BioMed Holdings paid its 3 named executives $5.2M in total in FY2025 (Dec). CEO David P. Hochman was paid $2.3M of that.

Name
David P. HochmanChief Executive Officer & Chairman
Darren R. ShermanPresident & Chief Operating Officer
Andrew L. TaylorChief Financial Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Orchestra BioMed Holdings. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board5

See all
  • Eric S. FainLead independent director · 2 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
  • Jason AryehDirector · 2 yr on the boardIndependentCompensation, Nominating and Corporate Governance (Chair)—Paid as an executive
  • David PacittiDirector · 1 yr on the boardIndependentAudit, Compensation—Paid as an executive
  • John MackDirector · 1 yr on the boardIndependentAudit—Paid as an executive
  • Chris ClearyDirector · 0 yr on the boardIndependentAudit—Paid as an executive

The board of the latest proxy (FY2025).

Shared directors

Activity

  1. Pay
    Orchestra BioMed Holdings CEO pay rose 18% to $2.3M. The stock rose 4% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Orchestra BioMed Holdings CFO pay rose 14% to $1.2M. The stock rose 4% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Orchestra BioMed Holdings CEO pay fell 72% to $1.9M. The stock fell 56% in FY2024 (Dec).
    DEF 14A
  4. Pay
    Orchestra BioMed Holdings COO pay fell 72% to $1.8M. The stock fell 56% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Orchestra BioMed Holdings CFO pay fell 56% to $1.1M. The stock fell 56% in FY2024 (Dec).
    DEF 14A
  6. Board
    John Mack joined the board of Orchestra BioMed Holdings. John Mack sits on no other public board.
    3
  7. Board
    Chris Cleary joined the board of Orchestra BioMed Holdings. Chris Cleary now sits on 4 public boards.
    3
  8. Pay
    Orchestra BioMed Holdings CEO pay rose 119% to $6.9M. The stock fell 9% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Orchestra BioMed Holdings COO pay rose 106% to $6.4M. The stock fell 9% in FY2023 (Dec).
    DEF 14A
  10. Board
    Pamela Ann Connealy joined the board of Orchestra BioMed Holdings. Pamela Ann Connealy sits on no other public board.
    3
  11. Board
    Jason Aryeh joined the board of Orchestra BioMed Holdings. Jason Aryeh now sits on 3 public boards.
    3
  12. Board
    Eric S. Fain joined the board of Orchestra BioMed Holdings. Eric S. Fain sits on no other public board.
    3
  13. Board
    David Pacitti joined the board of Orchestra BioMed Holdings. David Pacitti sits on no other public board.
    3

Filings6

See all
Proxy statementDEF 14AApr 29, 2026FY2025
Annual report10-KMar 12, 2026FY2025
Proxy statementDEF 14AApr 30, 2025FY2024
Annual report10-KMar 31, 2025FY2024
Proxy statementDEF 14AApr 30, 2024FY2023
Annual report10-KMar 27, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data